Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 7.54B |
| Revenue (ttm) | 2.58B |
| Net Income (ttm) | 759.90M |
| Shares Out | 26.99M |
| EPS (ttm) | 27.85 |
| PE Ratio | 10.03 |
| Forward PE | 27.23 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,256 |
| Open | 287.49 |
| Previous Close | 287.29 |
| Day's Range | 276.66 - 288.52 |
| 52-Week Range | 211.43 - 343.12 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 339.75 (+21.63%) |
| Earnings Date | Apr 30, 2026 |
About BIO
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory e... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BIO stock is "Buy." The 12-month stock price target is $339.75, which is an increase of 21.63% from the latest price.
News
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad Laboratories Earnings Call Transcript: Q4 2025
Q4 and full year 2025 results met revised revenue and operating margin guidance, but gross margin was pressured by supply chain costs. Diagnostics returned to growth, ddPCR saw strong QX700 sales, and free cash flow was robust. 2026 guidance calls for modest revenue growth and margin improvement.
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...
Bio-Rad Laboratories Earnings Call Transcript: Q3 2025
Q3 2025 saw stable revenue and margin outperformance despite macro headwinds, with strong process chromatography growth offsetting weakness in core Life Science and Clinical Diagnostics segments. Guidance for 2025 remains unchanged, with margin improvement and cautious optimism for 2026.
Bio-Rad Reports Third-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
It's time to scoop up undervalued stocks in this critical sector of the economy
Expanding your horizons and considering neglected sectors can help you identify bargain opportunities while defending your investment portfolio from a stock-market decline.
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Biorad Medisys announces its entry into the US market with the launch of its new subsidiary Medtimo Inc.
PUNE, India, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Biorad Medisys, an Indian medical device manufacturer with a global footprint, has announced its entry into the US market with the launch of its subsidi...
Bio-Rad Laboratories Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Q2 delivered strong revenue and margin gains, supported by process chromatography, consumables, and the Stilla acquisition. The expanded ddPCR portfolio and operational improvements are set to drive growth, while capital allocation remains focused on reinvestment and strategic acquisitions.
Bio-Rad Laboratories Transcript: Status Update
Digital PCR market estimates have been revised to $600 million, with growth rates now projected in the mid to high single digits, driven by new product launches and strong consumables pull-through. The expanded portfolio and validated droplet technology position the business for multi-year growth, especially as adoption accelerates in clinical and research applications.
Bio-Rad's Management to Participate in Upcoming Investor Conferences
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that members of the com...
Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings
Bio-Rad Laboratories, Inc. BIO reported better-than-expected second-quarter financial results on Thursday.
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced today that the company's mana...
Bio-Rad Laboratories Earnings Call Transcript: Q2 2025
Q2 2025 delivered revenue and margin above expectations, driven by process chromatography and resilient consumables, despite ongoing softness in academic and biotech markets. Guidance for 2025 was raised, reflecting reduced tariff headwinds and the Stilla acquisition.
Bio-Rad Reports Second-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Raja...
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t...
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new ...
Bio-Rad's Management to Host Investor Meetings During Jefferies Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie...
Bio-Rad Laboratories Transcript: RBC Capital Markets Global Healthcare Conference 2025
Leadership is focused on operational improvements and margin expansion amid market headwinds. Guidance reflects ongoing softness in academia, biotech, and China, with tariffs and policy uncertainty factored in. M&A strategy targets on-market assets, with the Stilla deal set to close by Q3.
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executiv...
Bio-Rad Laboratories Earnings Call Transcript: Q1 2025
Q1 2025 results exceeded consensus for revenue and margin despite macro and funding headwinds, with strong process chromatography growth and stable diagnostics outside China. Guidance was lowered due to tariffs and softer academic/biotech demand, but free cash flow and share buybacks remain robust.
Bio-Rad Reports First-Quarter 2025 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t...